Q-omics provides the consensus-scored KRT39 profile across patient tissues and cancer cell-line models. KRT39 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT39 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, KRT39 RNA expression shows 10,608 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where KRT39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT39 survival associations across molecular data types. KRT39 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT39 RNA expression–survival associations across cancer types. High KRT39 expression shows unfavorable associations in KIRC, HNSC, KIRP and READ, but favorable associations in MESO and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT39 RNA expression.
This table summarizes KRT39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for KRT39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT39 shows lower tumor expression in KICH and LUSC and higher tumor expression in LUAD, CHOL, ESCA and COAD. The KICH box plot shows higher KRT39 RNA expression in normal versus tumor tissue (log2 FC = −0.176, t-test p < 0.001).
This table shows molecular features associated with KRT39 in patient tissues and cancer cell lines. In patient samples, KRT39 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
